Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus and were either receiving no current treatment or currently treated with a sulfonylurea, metformin, or a combination of a sulfonylurea and metformin but experiencing inadequate glycemic control. Subjects qualified as receiving no current treatment if 1 of the following conditions applied:~  * Subject was newly diagnosed (ie, had not received any treatment).~ * Subject was treated with diet and exercise alone for the 3 months prior to Screening~ * Subject had received \<7 continuous days of any antidiabetic therapy within the 3 months prior to Screening.~ * Subject had a diagnosis of type 2 diabetes mellitus based on current American Diabetes Association criteria: fasting plasma glucose ≥126 mg/dL, oral glucose tolerance test at 2 hours after administration of the glucose load must have been ≥200 mg/dL, or symptoms of diabetes plus casual plasma glucose ≥200 mg/dL.~* Body mass index ≥23 kg/m2 and ≤40 kg/m2.~* Fasting C-peptide concentration ≥0.8 ng/mL.~* Glycosylated hemoglobin concentration between 6.8% and 11.0%.~* Fasting plasma glucose \>126 mg/dL at Screening.~* No treatment within the 3 months prior to Screening with any other agents known to have effects on glucose (other than as described above, a sulfonylurea, metformin, or a combination of a sulfonylurea and metformin in subjects on antidiabetics), including but not limited to the following:~  * Other antidiabetic agents~ * Investigational antidiabetic agents~ * Niacin~ * Regular use of systemic glucocorticoids.~ * No treatment within the 3 months prior to Screening with weight-loss drugs~ * If taking other non-excluded medications, must have been on a stable dose of medication for at least 4 weeks.~* Diastolic blood pressure ≤110 mm Hg and a systolic pressure of ≤180 mm Hg.~* Female subjects could neither be pregnant (confirmed by laboratory testing) nor lactating, and if of childbearing potential must have been practicing adequate contraception.~* Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.~* No major illness or debility that in the investigator's opinion prohibited the subject from completing the study.~* Hemoglobin ≥12 g/dL for males and ≥10 g/dL for females.~* Hepatic transaminase ≤2 x upper limit of normal.~Exclusion Criteria:~* History of cancer, other than squamous cell or basal cell carcinoma of the skin, that had not been in full remission for at least 1 year prior to Screening.~* History of proteinuria \>1000 mg/day on a 12- or 24-hour urine collection OR a urine albumin/creatinine ratio \>1000 μg/mg at Screening. If elevated, the subject was to be rescreened within 1 week.~* Serum creatinine ≥2.0 mg/dL.~* History of proliferative diabetic retinopathy OR any history of laser-treated retinopathy.~* History of treated peripheral or autonomic neuropathy.~* History of systolic dysfunction congestive heart failure.~* History of myocardial infarction within 1 year prior to Screening.~* History of ulcerative colitis or Crohn's disease.~* History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.~* History of a psychiatric disorder that would affect the subject's ability to participate in the study.~* History of anaphylactic reaction(s) to any drug.~* History of angioedema.~* History of alcohol or substance abuse within the last 2 years.~* History of any surgery that could potentially affect the absorption of the study drug.~* Receipt of any investigational drug within the preceding 30 days or a history of receipt of an investigational antidiabetic drug within the preceding 90 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 6.25 mg QD (Type: EXPERIMENTAL): None
- Alogliptin 12.5 mg QD (Type: EXPERIMENTAL): None
- Alogliptin 25 mg QD (Type: EXPERIMENTAL): None
- Alogliptin 50 mg QD (Type: EXPERIMENTAL): None
- Alogliptin 100 mg QD (Type: EXPERIMENTAL): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).